Ryan's District Boards

By Ben Hirschler BARCELONA (Reuters) - An experimental cholesterol-lowering drug from Sanofi and Regeneron Pharmaceuticals roughly halved the number of heart attacks and strokes in a clinical trial, researchers reported on Sunday. The injectable drug, alirocumab, is from a new class of medicines, which are also being developed by Amgen and Pfizer. They lower "bad" LDL cholesterol in a new way and are widely expected to reap multibillion-dollar sales. Sanofi and Regeneron said in July that nine big studies showed consistent LDL reductions with alirocumab, but details from four of these trials have only now been unveiled at the European Society of Cardiology annual meeting in Barcelona.